The annual incidence of ovarian cancer is about 15 If a family included three or more subjects with a relevant cancer and direct vertical transmission or transmission through a male, the family was considered compatible with autosomal dominant (AD) inheritance. Using these criteria, 17 pedigrees were consistent with AD inheritance but only one is currently suitable for linkage studies. This was because of a lack of tissue or blood samples for DNA extraction, and also in some cases because of an inability to confirm the diagnosis in some family members ( fig 1A, B) .
Of the AD families, one contained six cases of ovarian cancers, 10 families included a combination of breast cancer (either unilateral or bilateral) and at least one ovarian cancer, and the remaining six families contained a combination of ovarian, breast, and other cancers such as testicular or gastrointestinal cancers.
One of these six families also contained a subject with Hodgkin's lymphoma (table 2) .
Those families not meeting the above criteria for AD inheritance included 15 families with one or two ovarian cancers, 14 families with breast and ovarian cancers, and the remaining 10 families with ovarian cancer along with breast, gastrointestinal, and cervical cancers, and in two of these families a malignant melanoma was seen ( 3A) . Where the parents were still living, all parents and spouses of those considered to be at risk who were resident in the region attended for counselling and were tested. Therefore no subject was tested whose parent (if unaffected) had not also been tested.
Following testing, these 47 patients were then recategorised as being either at high risk (greater than 95% probability of carrying the gene based on DNA studies with linked polymorphisms) or low risk (less than 5% risk of carrying the gene) ( fig 3B) . gynaecologist with a special interest in gynaecological oncology. This screening policy was adopted as a compromise in Aberdeen, as the effectiveness of the above screening strategies
is as yet unproven. While individual centres are attempting to set up protocols for and trials of screening for ovarian cancer in order to ascertain the effectiveness of various forms of surveillance, it is also hoped that in the near future a national trial will begin which will audit the outcome of such screening programmes in women in different at risk categories. People who present to our clinic Aberdeen with a family history including ovarian cancer are given a personal risk assessment based on their family history, and if they are thought to be at a high risk of developing breast or ovarian cancer themselves are offered the opportunity of entering our screening programme. If the patient is thought to be a member of an autosomal dominant ovarian cancer family, or at the patient's request, they are offered the opportunity to discuss prophylactic surgery with both a clinical geneticist and a gynaecologist. To date, all those discussed in this paper who are considered to be at high risk of developing ovarian cancer have opted to enter our screening programme.
Following discovery of a strong candidate for the BRCA1 gene,67 the four genes relating to HNPCC23-26 and localisation ofthe BRCA227 gene, direct mutation testing may soon be possible in a number of families. Very few of our families would be suitable for linkage as the number of affected subjects for whom samples would be available would be inadequate. However, most families could be submitted for mutation testing for BRCA1 and eventually BRCA2, as in most families blood or tissue samples from many of the affected relatives are available. This may eventually give information regarding the likelihood that it is the segregation of a pathological mutation which is associated with the disease in that family.
When direct mutation testing becomes available, there will be increased demand on clinical and laboratory time. These patients will require pretest counselling, whether or not they opt to proceed to DNA testing.928
Predictive testing carries implications for lifestyle similar to other adult onset genetic disorders, such as Huntington's disease. However, as can be seen from the results of DNA analysis in family 1 mentioned above9 (fig 2) , more accurate identification of high risk patients can result in fewer people requiring screening or prophylactic surgery. Potential health benefits exist if a decision regarding surgery is postponed because of the unwanted effects of early mastectomy and oophorectomy if these prove to be unnecessary. Therefore DNA analysis can provide reassurance to a majority, and by more accurate targeting of those who require it, associated financial savings for screening and surgical services.
It is interesting to note (from fig 3) that a higher number of men than women were at 50% risk before testing, and subsequently tested at high risk compared to women, yet there were fewer men than women at 25% and 12-5% risk who came forward for testing. It is likely that this higher proportion of males in the 50% category exists because they have not been "screened out" by actually developing a cancer themselves.
It would be interesting in the future to estimate the cost in terms of genetic testing and counselling and prophylactic surgery, set against costs saved by not screening those who do not carry the mutant allele in this family, but such a study would necessarily be the basis of further research. 
